Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “BDSX.”

Biodesix is a leading data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Yasin Keshvargar, counsel Alain Kuyumjian and associate Johnathan M. Nixon. Partner David R. Bauer and associates Yifu Chen and Brette L. Trost provided intellectual property advice. The environmental team included counsel Loyti Cheng and associate Alexandra Munson. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post